AU2013280875B2 - Phenoxyethyl piperidine compounds - Google Patents

Phenoxyethyl piperidine compounds Download PDF

Info

Publication number
AU2013280875B2
AU2013280875B2 AU2013280875A AU2013280875A AU2013280875B2 AU 2013280875 B2 AU2013280875 B2 AU 2013280875B2 AU 2013280875 A AU2013280875 A AU 2013280875A AU 2013280875 A AU2013280875 A AU 2013280875A AU 2013280875 B2 AU2013280875 B2 AU 2013280875B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013280875A
Other languages
English (en)
Other versions
AU2013280875A1 (en
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013280875A1 publication Critical patent/AU2013280875A1/en
Application granted granted Critical
Publication of AU2013280875B2 publication Critical patent/AU2013280875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013280875A 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds Active AU2013280875B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
AU2013280875A1 AU2013280875A1 (en) 2014-12-04
AU2013280875B2 true AU2013280875B2 (en) 2015-09-24

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013280875A Active AU2013280875B2 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Country Status (42)

Country Link
US (2) US8962659B2 (cg-RX-API-DMAC7.html)
EP (1) EP2867207B1 (cg-RX-API-DMAC7.html)
JP (1) JP6127136B2 (cg-RX-API-DMAC7.html)
KR (1) KR101653476B1 (cg-RX-API-DMAC7.html)
CN (1) CN104411684B (cg-RX-API-DMAC7.html)
AP (1) AP2014008164A0 (cg-RX-API-DMAC7.html)
AR (1) AR091429A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013280875B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031616B1 (cg-RX-API-DMAC7.html)
CA (1) CA2875569C (cg-RX-API-DMAC7.html)
CL (1) CL2014003535A1 (cg-RX-API-DMAC7.html)
CO (1) CO7151507A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140553A (cg-RX-API-DMAC7.html)
CY (1) CY1119425T1 (cg-RX-API-DMAC7.html)
DK (1) DK2867207T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000287A (cg-RX-API-DMAC7.html)
EA (1) EA024392B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14033267A (cg-RX-API-DMAC7.html)
ES (1) ES2644812T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400288A (cg-RX-API-DMAC7.html)
HR (1) HRP20171515T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034425T2 (cg-RX-API-DMAC7.html)
IL (1) IL236219A (cg-RX-API-DMAC7.html)
JO (1) JO3296B1 (cg-RX-API-DMAC7.html)
LT (1) LT2867207T (cg-RX-API-DMAC7.html)
MA (1) MA37686B1 (cg-RX-API-DMAC7.html)
ME (1) ME02840B (cg-RX-API-DMAC7.html)
MX (1) MX345324B (cg-RX-API-DMAC7.html)
MY (1) MY173878A (cg-RX-API-DMAC7.html)
NZ (1) NZ701933A (cg-RX-API-DMAC7.html)
PE (1) PE20150182A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500009B1 (cg-RX-API-DMAC7.html)
PL (1) PL2867207T3 (cg-RX-API-DMAC7.html)
PT (1) PT2867207T (cg-RX-API-DMAC7.html)
RS (1) RS56452B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201408641UA (cg-RX-API-DMAC7.html)
SI (1) SI2867207T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000501A1 (cg-RX-API-DMAC7.html)
TW (1) TWI599561B (cg-RX-API-DMAC7.html)
UA (1) UA114325C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014004229A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408632B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
SI3083562T1 (sl) * 2013-12-17 2017-11-30 Eli Lilly And Company Derivati fenoksietil cikličnih aminov in njihova aktivnost kot modulatorji EP4 receptorja
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
CA3063632A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
EP3889134B1 (en) 2019-01-22 2024-09-25 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250818A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
BR0308738A (cg-RX-API-DMAC7.html) * 2002-03-18 2005-01-11
CN1735597A (zh) * 2003-01-10 2006-02-15 霍夫曼-拉罗奇有限公司 作为前列腺素激动剂的2-哌啶酮衍生物
AU2004268839A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
KR20070006891A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
DK2565191T3 (da) 2008-05-14 2014-11-10 Astellas Pharma Inc 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
CA2789665C (en) 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
JP5956448B2 (ja) * 2010-09-21 2016-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US9120824B2 (en) 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
DK2729445T3 (en) * 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250818A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds

Also Published As

Publication number Publication date
CA2875569C (en) 2016-04-19
UA114325C2 (uk) 2017-05-25
MA37686A1 (fr) 2016-09-30
JP2015522018A (ja) 2015-08-03
KR20150013893A (ko) 2015-02-05
PE20150182A1 (es) 2015-02-13
NZ701933A (en) 2017-01-27
TWI599561B (zh) 2017-09-21
AR091429A1 (es) 2015-02-04
US20150126555A1 (en) 2015-05-07
JO3296B1 (ar) 2018-09-16
CL2014003535A1 (es) 2015-05-08
US9402838B2 (en) 2016-08-02
MA37686B1 (fr) 2017-04-28
AP2014008164A0 (en) 2014-12-31
HRP20171515T1 (hr) 2017-11-17
MX2014015953A (es) 2015-07-17
CO7151507A2 (es) 2014-12-29
PT2867207T (pt) 2017-11-01
PH12015500009A1 (en) 2015-03-02
IL236219A (en) 2017-12-31
RS56452B1 (sr) 2018-01-31
ES2644812T3 (es) 2017-11-30
GT201400288A (es) 2015-08-27
MX345324B (es) 2017-01-25
TW201412717A (zh) 2014-04-01
EP2867207A1 (en) 2015-05-06
CY1119425T1 (el) 2018-03-07
CR20140553A (es) 2015-02-04
TN2014000501A1 (en) 2016-03-30
EP2867207B1 (en) 2017-08-09
ME02840B (me) 2018-01-20
BR112014031616A2 (pt) 2017-06-27
AU2013280875A1 (en) 2014-12-04
EA201492255A1 (ru) 2015-03-31
US20140005226A1 (en) 2014-01-02
IL236219A0 (en) 2015-02-01
SG11201408641UA (en) 2015-01-29
EA024392B1 (ru) 2016-09-30
US8962659B2 (en) 2015-02-24
WO2014004229A1 (en) 2014-01-03
ZA201408632B (en) 2017-06-28
PH12015500009B1 (en) 2020-10-09
DK2867207T3 (en) 2017-09-11
MY173878A (en) 2020-02-26
CN104411684B (zh) 2016-08-24
KR101653476B1 (ko) 2016-09-01
PL2867207T3 (pl) 2018-01-31
CA2875569A1 (en) 2014-01-03
JP6127136B2 (ja) 2017-05-10
HUE034425T2 (en) 2018-02-28
LT2867207T (lt) 2017-10-10
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
BR112014031616B1 (pt) 2022-06-21
HK1203937A1 (en) 2015-11-06
SI2867207T1 (sl) 2017-10-30
DOP2014000287A (es) 2015-01-31

Similar Documents

Publication Publication Date Title
AU2013280875B2 (en) Phenoxyethyl piperidine compounds
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性
JP6148400B2 (ja) フェノキシエチルジヒドロ−1h−イソキノリン化合物
US9000043B2 (en) Phenoxyethoxy compounds
EP2867218A1 (en) Dimethyl-benzoic acid compounds
HK1203937B (en) Phenoxyethyl piperidine compounds
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)